Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 915

Sort by

Sort Order Select

Journal Articles

The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia

Audrey Dauba, Emmanuelle Näser, Antoine Nouhaud, Eric Delabesse, Bastien Gerby, Ahmed Amine Khamlichi

Blood Adv (2025) 9 (19): 5010–5014.

https://doi.org/10.1182/bloodadvances.2025016313

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y. Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani

Blood Adv (2025) 9 (19): 4946–4950.

https://doi.org/10.1182/bloodadvances.2025016731

Published: 2025

Includes: Supplemental data

Journal Articles

A simple and efficient method for the robust expansion of human ILC2s to prevent acute GVHD

Danny W. Bruce, Sonia J. Laurie, Yan Xing, Heather E. Stefanski, Keli L. Hippen, Alec D. Wilkinson, Mark G. Woodcock, James M. Coghill, Jr., Karen P. McKinnon, Bruce R. Blazar, Jonathan S. Serody

Blood Adv (2025) 9 (19): 4951–4962.

https://doi.org/10.1182/bloodadvances.2024013609

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting Siglec–sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma

Arghya Ray, Leutz Buon, Xueping Wan, Ting Du, Yan Song, Sindhu C. Pillai, Md Abu Musa, Teng Fang, Minxing Wang, Kenneth C. Anderson

Blood Adv (2025) 9 (19): 5085–5090.

https://doi.org/10.1182/bloodadvances.2025015980

Published: 2025

Includes: Supplemental data

Journal Articles

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel

Blood Adv (2025) 9 (19): 5070–5084.

https://doi.org/10.1182/bloodadvances.2025016824

Published: 2025

Includes: Supplemental data

Journal Articles

Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders

Willian R. Gomes, Shan Hama, Giorgio Napolitani, Amandine Tan, Luiz Fernando B. Catto, Flávia S. Donaires, Bárbara A. Santana, Vinícius S. Carvalho, Edson Z. Martinez, Antonio Condino-Neto, Mohammad M. Karimi, Ghulam J. Mufti, Rodrigo T. Calado

Blood Adv (2025) 9 (19): 4790–4805.

https://doi.org/10.1182/bloodadvances.2025015976

Published: 2025

Includes: Supplemental data

Journal Articles

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Frits van Rhee, Anita D’Souza, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood Adv (2025) 9 (19): 4806–4809.

https://doi.org/10.1182/bloodadvances.2025016695

Published: 2025

Journal Articles

Predictive markers for the efficacy of CAR T-cell therapy: the interplay of CAR-T fitness and systemic immunity

Kwai Han Yoo, Szymon Jakub Szymura, Zhenyuan Dong, Anmol Kandel, Soung-chul Cha, Larry W Kwak

Blood Adv bloodadvances.2025017873.

https://doi.org/10.1182/bloodadvances.2025017873

Published: 2025

Journal Articles

Time to redefine HHV-8 MCD and KICS criteria?

Romain Stammler, Yannick Dieudonné, Anthony Vanjak, Eric Oksenhendler, Lionel Galicier, David Boutboul

Blood Adv bloodadvances.2025018106.

https://doi.org/10.1182/bloodadvances.2025018106

Published: 2025

Journal Articles

Applying principles of vaccine development to oncomicrobial vaccines

Cody A Despins, Nicholas JP Viegas, Robert A Holt

Blood Adv bloodadvances.2024015610.

https://doi.org/10.1182/bloodadvances.2024015610

Published: 2025

Journal Articles

Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

Blood Adv bloodadvances.2025017012.

https://doi.org/10.1182/bloodadvances.2025017012

Published: 2025

Journal Articles

Dual Anti-CD19/22 and Anti-BCMA CAR-T cell therapy in a patient with multiple myeloma and secondary B-ALL

Malte Roerden, Luca Hensen, Britta Besemer, Friederike Schwartz, Kristina Reuss, Alisha Weiss-Haug, Lennart Harland, Franziska Ginsberg, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke

Blood Adv bloodadvances.2025017770.

https://doi.org/10.1182/bloodadvances.2025017770

Published: 2025

Journal Articles

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

Blood Adv bloodadvances.2025017081.

https://doi.org/10.1182/bloodadvances.2025017081

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor-Specific Immune Responses and Biomarkers in pediatric High-Risk Hodgkin Lymphoma Patients

Keri Toner, Lindsay A Renfro, Hema Dave, Gloria Pezzella, Qinglin Pei, Lisa Giulino-Roth, Terzah M. Horton, Frank G Keller, Kara M Kelly, Sharon M Castellino, Catherine M. Bollard

Blood Adv bloodadvances.2025016797.

https://doi.org/10.1182/bloodadvances.2025016797

Published: 2025

Includes: Supplemental data

Journal Articles

Do not forget vaccinations in patients on Ig replacement

Sigrun Einarsdottir, Silvia Escribano Serrat, Marina Gomez-Llobell, Malin L Hultcrantz, Mini Kamboj, Miguel-Angel Perales, Roni Shouval, Zainab Shahid, Per Ljungman

Blood Adv bloodadvances.2025018127.

https://doi.org/10.1182/bloodadvances.2025018127

Published: 2025

Journal Articles

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Véronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill, Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Blood Adv (2025) 9 (18): 4693–4704.

https://doi.org/10.1182/bloodadvances.2025015834

Published: 2025

Includes: Supplemental data

Journal Articles

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Taku Kikuchi, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Haruka Sawada, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida, Nobuhiro Tsukada

Blood Adv (2025) 9 (18): 4716–4719.

https://doi.org/10.1182/bloodadvances.2025017174

Published: 2025

Includes: Supplemental data

Journal Articles

mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Taylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, Emma Louise Bishop, Bryan Marzullo, Hannah Victoria Giles, Dr, Graham McIlroy, Paul Ferguson, Bhuvan Kishore, Kate Rogers, Nuri Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, Guy Pratt, Sarah Dimeloe

Blood Adv bloodadvances.2025016439.

https://doi.org/10.1182/bloodadvances.2025016439

Published: 2025

Includes: Supplemental data

Journal Articles

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study

John C. Panetta, Aimee C. Talleur, Swati Naik, Stephen Gottschalk, Markos Leggas

Blood Adv (2025) 9 (18): 4676–4682.

https://doi.org/10.1182/bloodadvances.2025015928

Published: 2025

Includes: Supplemental data

Journal Articles

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

Fausto Alfredo Rios-Olais, Talal Hilal

Blood Adv (2025) 9 (18): 4673–4675.

https://doi.org/10.1182/bloodadvances.2025016176

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

A simple and efficient method for the robust expansion of human ILC2s to prevent acute GVHD

Targeting Siglec–sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel

Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia

Predictive markers for the efficacy of CAR T-cell therapy: the interplay of CAR-T fitness and systemic immunity

Time to redefine HHV-8 MCD and KICS criteria?

Applying principles of vaccine development to oncomicrobial vaccines

Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

Dual Anti-CD19/22 and Anti-BCMA CAR-T cell therapy in a patient with multiple myeloma and secondary B-ALL

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

Tumor-Specific Immune Responses and Biomarkers in pediatric High-Risk Hodgkin Lymphoma Patients

Do not forget vaccinations in patients on Ig replacement

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only